Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;48(5):1248-1254.
doi: 10.1111/jog.15184. Epub 2022 Feb 10.

Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy

Hiroshi Nakazawa  1 , Shoji Nagao  2 , Moyu Narita  1 , Takashi Shibutani  1 , Tomoatsu Jimi  1 , Hiroko Yano  1 , Miho Kitai  1 , Takaya Shiozaki  1 , Satoshi Yamaguchi  1
Affiliations

Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy

Hiroshi Nakazawa et al. J Obstet Gynaecol Res. 2022 May.

Abstract

Aim: Several years have passed since olaparib maintenance therapy was approved in patients with platinum sensitive recurrent ovarian cancer (PSROC). We speculated that the response to platinum-based chemotherapy (PBC) would be impaired at the time of recurrence after olaparib maintenance therapy. We conducted a noninterventional retrospective study to clarify this clinical question in a single institution.

Methods: We included all patients with PSROC who received olaparib after second or later line of PBC between April 18, 2018, and August 31, 2021. We evaluated the effect of olaparib maintenance therapy on PBC after progression.

Results: We identified 42 patients who received olaparib maintenance therapy after second or later line of PBC. Twenty-four patients relapsed after olaparib maintenance therapy, and 17 patients received PBC again. Four of 17 patients (complete response 2, partial response 2) responded to the PBC. The median progression-free survival was longer in patients with platinum-free interval ≥12 months than platinum-free interval of 6-12 months (9.7 vs 2.6 months, hazard ratio, 0.20: 95% confidence interval, 0.04-0.90; p = 0.04).

Conclusions: In the patients with PSROC who experienced disease progression after olaparib maintenance therapy, especially in those with platinum-free interval of 6-12 months, the response to subsequent PBC was extremely poor. The efficiency of re-administration of PBC for PSROC patients with a short-term recurrence after olaparib treatment may need to be reconsidered.

Keywords: maintenance chemotherapy; ovarian neoplasms; poly (ADP-ribose) polymerase inhibitors; recurrence; treatment outcome.

PubMed Disclaimer

References

    1. Nagase S, Ohta T, Takahashi F, Yaegashi N. Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: annual patient report for 2017 and annual treatment report for 2012. J Obstet Gynaecol Res. 2021;47(5):1631-42.
    1. McMullen M, Karakasis K, Madariaga A, Oza A. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer. Cancer. 2020;12(6):1607.
    1. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:247.
    1. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452-8.
    1. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-92.

LinkOut - more resources